• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

皮质类固醇能否降低酒精性肝炎的死亡率?随机试验的荟萃分析。

Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials.

作者信息

Imperiale T F, McCullough A J

机构信息

Case Western Reserve University School of Medicine, Cleveland, Ohio.

出版信息

Ann Intern Med. 1990 Aug 15;113(4):299-307. doi: 10.7326/0003-4819-113-4-299.

DOI:10.7326/0003-4819-113-4-299
PMID:2142869
Abstract

PURPOSE

To determine whether corticosteroids affect short-term mortality from alcoholic hepatitis.

DATA IDENTIFICATION

Studies published from 1966 to 1989 were identified through a MEDLINE computer search and an extensive manual search of the bibliographies of identified articles.

STUDY SELECTION

We found 11 randomized studies (10 of which were placebo controlled) that assessed mortality in hospitalized patients diagnosed with acute alcoholic hepatitis and treated with corticosteroids.

DATA EXTRACTION

Two critical appraisers independently evaluated trial quality and abstracted quantitative data on clinical characteristics of the populations, interventions, and all-cause mortality.

RESULTS OF DATA SYNTHESIS

Overall, the protective efficacy (or percent reduction in mortality) of corticosteroids was 37% (95% CI, 20% to 50%). Protective efficacy was higher among trials with higher quality scores and trials that excluded subjects with active gastrointestinal bleeding. In subjects with hepatic encephalopathy, protective efficacy was 34% overall (CI, 15% to 48%). It was also higher among trials with higher quality scores and trials excluding subjects with acute gastrointestinal bleeding, but was not present among trials with lower quality scores or trials that did not exclude subjects with acute gastrointestinal bleeding. In subjects without hepatic encephalopathy, corticosteroids had no protective effect, and this lack of efficacy was consistent across all trial subgroups.

CONCLUSIONS

These results suggest that corticosteroids reduce short-term mortality in patients with acute alcoholic hepatitis who have hepatic encephalopathy, that the protective effect depends on the exclusion criterion of acute gastrointestinal bleeding and is influenced by trial quality, and that corticosteroids are of no benefit in patients without hepatic encephalopathy.

摘要

目的

确定皮质类固醇激素是否会影响酒精性肝炎的短期死亡率。

数据识别

通过医学文献数据库(MEDLINE)计算机检索以及对已识别文章的参考文献进行广泛的人工检索,找出1966年至1989年发表的研究。

研究选择

我们发现了11项随机研究(其中10项为安慰剂对照研究),这些研究评估了被诊断为急性酒精性肝炎并接受皮质类固醇激素治疗的住院患者的死亡率。

数据提取

两名关键评估者独立评估试验质量,并提取有关研究人群的临床特征、干预措施和全因死亡率的定量数据。

数据综合结果

总体而言,皮质类固醇激素的保护效果(或死亡率降低百分比)为37%(95%置信区间,20%至50%)。在质量评分较高的试验以及排除有活动性胃肠道出血受试者的试验中,保护效果更高。在患有肝性脑病的受试者中,总体保护效果为34%(置信区间,15%至48%)。在质量评分较高的试验以及排除急性胃肠道出血受试者的试验中,保护效果也更高,但在质量评分较低的试验或未排除急性胃肠道出血受试者的试验中则不存在这种效果。在没有肝性脑病的受试者中,皮质类固醇激素没有保护作用,并且在所有试验亚组中这种无效性都是一致的。

结论

这些结果表明,皮质类固醇激素可降低患有肝性脑病的急性酒精性肝炎患者的短期死亡率,保护作用取决于急性胃肠道出血的排除标准,并受试验质量影响,且皮质类固醇激素对没有肝性脑病的患者没有益处。

相似文献

1
Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials.皮质类固醇能否降低酒精性肝炎的死亡率?随机试验的荟萃分析。
Ann Intern Med. 1990 Aug 15;113(4):299-307. doi: 10.7326/0003-4819-113-4-299.
2
Corticosteroids and occurrence of and mortality from infections in severe alcoholic hepatitis: a meta-analysis of randomized trials.皮质类固醇与重症酒精性肝炎感染的发生及死亡率:一项随机试验的荟萃分析
Liver Int. 2016 May;36(5):721-8. doi: 10.1111/liv.12939. Epub 2015 Sep 14.
3
Corticosteroids and alcoholic hepatitis.皮质类固醇与酒精性肝炎
Hepatology. 1991 Jan;13(1):199-201. doi: 10.1002/hep.1840130132.
4
Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis.药物干预治疗重症酒精性肝炎的疗效比较:系统评价和网络荟萃分析。
Gastroenterology. 2015 Oct;149(4):958-70.e12. doi: 10.1053/j.gastro.2015.06.006. Epub 2015 Jun 16.
5
Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy.泼尼松龙治疗重症急性酒精性肝炎合并自发性脑病患者的双盲对照试验。
Gastroenterology. 1980 Mar;78(3):524-9.
6
Corticosteroids Versus Pentoxifylline for Severe Alcoholic Hepatitis: A Sequential Analysis of Randomized Controlled Trials.皮质类固醇与己酮可可碱治疗重度酒精性肝炎:随机对照试验的序贯分析
J Clin Gastroenterol. 2016 Nov/Dec;50(10):871-881. doi: 10.1097/MCG.0000000000000585.
7
Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials.系统评价:糖皮质激素治疗酒精性肝炎——Cochrane肝胆组对随机临床试验的系统评价、荟萃分析及试验序贯分析
Aliment Pharmacol Ther. 2008 Jun;27(12):1167-78. doi: 10.1111/j.1365-2036.2008.03685.x. Epub 2008 Mar 20.
8
Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH.皮质类固醇可改善重症酒精性肝炎(AH)患者的短期生存率:对皮质类固醇治疗重症AH的最近三项随机安慰剂对照双盲试验的个体数据分析
J Hepatol. 2002 Apr;36(4):480-7. doi: 10.1016/s0168-8278(01)00289-6.
9
A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients.6-甲基泼尼松龙治疗急性酒精性肝炎的对照试验。附关于脑病患者已发表结果的说明。
Am J Gastroenterol. 1978 Apr;69(4):443-9.
10
[Is there a role for pentoxifylline in the treatment of alcoholic hepatitis?].己酮可可碱在酒精性肝炎治疗中有作用吗?
Gastroenterol Hepatol. 2016 Oct;39(8):560-5. doi: 10.1016/j.gastrohep.2015.10.004. Epub 2015 Nov 15.

引用本文的文献

1
Advances and Controversies in Acute Alcohol-Related Hepatitis: From Medical Therapy to Liver Transplantation.急性酒精性肝炎的进展与争议:从药物治疗到肝移植
Life (Basel). 2023 Aug 24;13(9):1802. doi: 10.3390/life13091802.
2
Therapeutic targets in alcohol-associated liver disease: progress and challenges.酒精性肝病的治疗靶点:进展与挑战
Therap Adv Gastroenterol. 2023 May 10;16:17562848231170946. doi: 10.1177/17562848231170946. eCollection 2023.
3
The Impact of Metabolic Syndrome on the Prognosis of High-Risk Alcoholic Hepatitis Patients: Redefining Alcoholic Hepatitis.
代谢综合征对高危酒精性肝炎患者预后的影响:重新定义酒精性肝炎
Gastroenterology Res. 2023 Feb;16(1):25-36. doi: 10.14740/gr1556. Epub 2023 Feb 28.
4
Hepatitis of an Unknown Etiology with Concomitant ITP.病因不明的肝炎合并免疫性血小板减少症
J Community Hosp Intern Med Perspect. 2023 Jan 10;13(1):67-71. doi: 10.55729/2000-9666.1150. eCollection 2023.
5
Neuromodulation Applied to Diseases: The Case of HRV Biofeedback.神经调节在疾病中的应用:以心率变异性生物反馈为例。
J Clin Med. 2022 Oct 8;11(19):5927. doi: 10.3390/jcm11195927.
6
Trends of Readmissions for Gastrointestinal Bleeding After Alcoholic Hepatitis: Analysis of the Nationwide Readmission Database.酒精性肝炎后胃肠道出血再入院趋势:全国再入院数据库分析
Gastroenterology Res. 2022 Jun;15(3):136-141. doi: 10.14740/gr1526. Epub 2022 Jun 2.
7
Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study.鉴定类固醇治疗严重酒精性肝炎的最佳治疗窗:一项世界性研究。
J Hepatol. 2021 Nov;75(5):1026-1033. doi: 10.1016/j.jhep.2021.06.019. Epub 2021 Jun 21.
8
Current Management and Future Treatment of Alcoholic Hepatitis.酒精性肝炎的当前管理与未来治疗
Gastroenterol Hepatol (N Y). 2020 Apr;16(4):178-189.
9
Alcoholic hepatitis: Diagnosis and prognosis.酒精性肝炎:诊断与预后
Clin Liver Dis (Hoboken). 2013 Apr 24;2(2):80-83. doi: 10.1002/cld.164. eCollection 2013 Apr.
10
Glucocorticosteroids for people with alcoholic hepatitis.用于酒精性肝炎患者的糖皮质激素。
Cochrane Database Syst Rev. 2019 Apr 9;4(4):CD001511. doi: 10.1002/14651858.CD001511.pub4.